Tags

Type your tag names separated by a space and hit enter

[Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care].
Pol Merkur Lekarski. 2004 May; 16 Suppl 1:96-9.PM

Abstract

This paper presents the efficacy and cost of therapy with azithromycin for the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Two subgroups were investigated: out-patients and hospitalized patients--20 in each group (17 women and 23 men). Azithromycin 500 mg was administered sequentially once daily. A complete physical examination including temperature, respiratory rate, cough, production and characteristics of sputum so as general aspects of quality of life assessed by COPD exacerbation questionnaire was made in hospitalized patients on a daily base and in a day 10-14 after the end of therapy. Out-patients were assessed in day 1, 3-5 days after the start of study drug treatment and 10-14 days after the end of therapy. Pulmonary function tests were assessed three times during the whole study course. The results of the study suggest similar duration of therapy with azithromycin in both study subgroups, whereas in out-patients decrease and regression of symptoms were statistically significantly quicker with tendency approximately the same in both study subgroups. The cost of therapy with azithromycin was similar in both subgroups but the complete cost of COPD exacerbation treatment was significantly lower in out-patients in comparison to hospitalized patients group (473.71 PLN and 2587.87 respectively).

Authors+Show Affiliations

Wojskowy Instytut Medyczny, Klinika Chorób Wewnetrznych, Pneumonologii i Alergologii CSK MON w Warszawie.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
English Abstract
Journal Article

Language

pol

PubMed ID

15524029

Citation

Faber, Małgorzata, et al. "[Evaluation of Clinical Effectiveness and Direct Costs of Azithromycin Treatment for Exacerbation of Chronic Obstructive Pulmonary Disease in Hospitalized Patients and Ambulatory Care]." Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego, vol. 16 Suppl 1, 2004, pp. 96-9.
Faber M, Jahnz-Rózyk K, Kucharczyk A, et al. [Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care]. Pol Merkur Lekarski. 2004;16 Suppl 1:96-9.
Faber, M., Jahnz-Rózyk, K., Kucharczyk, A., Targowski, T., From, S., & Mamełka, B. (2004). [Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care]. Polski Merkuriusz Lekarski : Organ Polskiego Towarzystwa Lekarskiego, 16 Suppl 1, 96-9.
Faber M, et al. [Evaluation of Clinical Effectiveness and Direct Costs of Azithromycin Treatment for Exacerbation of Chronic Obstructive Pulmonary Disease in Hospitalized Patients and Ambulatory Care]. Pol Merkur Lekarski. 2004;16 Suppl 1:96-9. PubMed PMID: 15524029.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Evaluation of clinical effectiveness and direct costs of azithromycin treatment for exacerbation of chronic obstructive pulmonary disease in hospitalized patients and ambulatory care]. AU - Faber,Małgorzata, AU - Jahnz-Rózyk,Karina, AU - Kucharczyk,Aleksandra, AU - Targowski,Tomasz, AU - From,Sławomir, AU - Mamełka,Beata, PY - 2004/11/5/pubmed PY - 2005/1/26/medline PY - 2004/11/5/entrez SP - 96 EP - 9 JF - Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego JO - Pol. Merkur. Lekarski VL - 16 Suppl 1 N2 - This paper presents the efficacy and cost of therapy with azithromycin for the treatment of patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Two subgroups were investigated: out-patients and hospitalized patients--20 in each group (17 women and 23 men). Azithromycin 500 mg was administered sequentially once daily. A complete physical examination including temperature, respiratory rate, cough, production and characteristics of sputum so as general aspects of quality of life assessed by COPD exacerbation questionnaire was made in hospitalized patients on a daily base and in a day 10-14 after the end of therapy. Out-patients were assessed in day 1, 3-5 days after the start of study drug treatment and 10-14 days after the end of therapy. Pulmonary function tests were assessed three times during the whole study course. The results of the study suggest similar duration of therapy with azithromycin in both study subgroups, whereas in out-patients decrease and regression of symptoms were statistically significantly quicker with tendency approximately the same in both study subgroups. The cost of therapy with azithromycin was similar in both subgroups but the complete cost of COPD exacerbation treatment was significantly lower in out-patients in comparison to hospitalized patients group (473.71 PLN and 2587.87 respectively). SN - 1426-9686 UR - https://www.unboundmedicine.com/medline/citation/15524029/[Evaluation_of_clinical_effectiveness_and_direct_costs_of_azithromycin_treatment_for_exacerbation_of_chronic_obstructive_pulmonary_disease_in_hospitalized_patients_and_ambulatory_care]_ L2 - http://www.diseaseinfosearch.org/result/7979 DB - PRIME DP - Unbound Medicine ER -